Daiichi Sankyo To Submit NDA For Inavir In Japan By Year End
This article was originally published in PharmAsia News
Following positive Phase III results for anti-influenza treatment Inavir (laninamivir), Daiichi Sankyo is preparing to submit an NDA for Inavir.
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.